Research raises possibility that tirzepatide could become first pharmaceutical treatment for the sleeping disorder
A drug used for type 2 diabetes and weight loss could reduce the severity of obstructive sleep apnoea (OSA) in people with obesity, research suggests, raising the possibility of the first pharmaceutical treatment for the condition.
Tirzepatide, which is made by Eli Lilly and Company, together with other medications such as Wegovy from Novo Nordisk, are part of a new wave of medications sometimes referred to as “skinny jabs” because they can result in dramatic weight loss.
About Author
More Stories
Revealed: Chinese researchers can access half a million UK GP records
The sinister psychology at the heart of populism | Letters
Brisk walking linked to lower risk of heart rhythm problems, study finds